Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DOO
3876
Bombardier Recreational Products
DOO
$4.77B
| $77.3K | ﹤0.01% |
1,208
-4,034
| -77% | -$272K |
|
3877
GoodRx Holdings
GDRX
$1.26B
| $77.2K | ﹤0.01% |
9,894
-19,500
| -66% | -$144K |
|
|
AFCG
3878
AFC Gamma
AFCG
$63.4M
| $77.1K | ﹤0.01% |
9,236
-8,128
| -47% | -$66.9K |
|
3879
TScan Therapeutics
TCRX
$52M
| $77K | ﹤0.01% |
+13,164
| New | +$104K |
|
3880
John Marshall Bancorp
JMSB
$329M
| $76.9K | ﹤0.01% |
4,412
-4,334
| -50% | -$73.7K |
|
3881
Alta Equipment Group
ALTG
$245M
| $76.5K | ﹤0.01% |
9,515
-10,896
| -53% | -$110K |
|
|
LENZ
3882
LENZ Therapeutics
LENZ
$168M
| $76.3K | ﹤0.01% |
4,412
-2,151
| -33% | -$37.6K |
|
3883
Turkcell
TKC
$4.79B
| $75.8K | ﹤0.01% |
10,000
| – | – |
|
3884
Organogenesis Holdings
ORGO
$239M
| $75.5K | ﹤0.01% |
26,954
-22,306
| -45% | -$59.9K |
|
3885
E.W. Scripps
SSP
$304M
| $75.4K | ﹤0.01% |
24,008
-32,111
| -57% | -$102K |
|
|
ONL
3886
Orion Office REIT
ONL
$160M
| $75.2K | ﹤0.01% |
20,942
-19,812
| -49% | -$67.8K |
|
3887
Actinium Pharmaceuticals
ATNM
$25M
| $75.1K | ﹤0.01% |
10,151
-9,218
| -48% | -$75.9K |
|
3888
Frontier Group Holdings
ULCC
$1.7B
| $75.1K | ﹤0.01% |
15,224
-20,575
| -57% | -$123K |
|
3889
Clarus
CLAR
$143M
| $75K | ﹤0.01% |
11,138
-10,446
| -48% | -$68.9K |
|
3890
Nathan's Famous
NATH
$402M
| $74.6K | ﹤0.01% |
1,100
-992
| -47% | -$67.1K |
|
3891
Microvision
MVIS
$79M
| $74.5K | ﹤0.01% |
4,688
-6,778
| -59% | -$134K |
|
|
AZUL
3892
DELISTED
Azul
AZUL
| $74.4K | ﹤0.01% |
18,600
-24,083
| -56% | -$141K |
|
|
OPTN
3893
DELISTED
OptiNose
OPTN
| $74.1K | ﹤0.01% |
4,749
-1,970
| -29% | -$33K |
|
3894
Akebia Therapeutics
AKBA
$252M
| $74.1K | ﹤0.01% |
72,603
-137,397
| -65% | -$170K |
|
3895
Pure Cycle
PCYO
$261M
| $73.9K | ﹤0.01% |
7,739
-7,175
| -48% | -$67.7K |
|
3896
iShares MSCI Europe Small-Cap ETF
IEUS
$185M
| $73.8K | ﹤0.01% |
1,320
| – | – |
|
|
NXDT
3897
NexPoint Diversified Real Estate Trust
NXDT
$238M
| $73.8K | ﹤0.01% |
13,341
-11,583
| -46% | -$66K |
|
3898
Pulse Biosciences
PLSE
$3.02B
| $73.5K | ﹤0.01% |
6,568
-4,756
| -42% | -$44.8K |
|
3899
Alico
ALCO
$283M
| $73.5K | ﹤0.01% |
2,836
-2,147
| -43% | -$58.1K |
|
3900
OppFi
OPFI
$803M
| $72.9K | ﹤0.01% |
21,511
-1,397
| -6% | -$4.25K |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.